Drug Profile
CB 008
Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Canopus BioPharma
- Developer Canopus BioPharma; Texas Biomedical Research Institute; Unknown
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ebola virus infections; Haemorrhage
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for research development in Ebola-virus-infections in USA (PO)
- 28 Jan 2019 No recent reports of development identified for research development in Haemorrhage(Prevention) in USA (PO)
- 19 Dec 2014 Early research in Ebola virus infections and Haemorrhagic syndrome (Prevention) in USA (PO)